LGD-4033 vs Myostatin Inhibitor
A side-by-side research comparison of LGD-4033 and Myostatin Inhibitor across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | LGD-4033 | Myostatin Inhibitor |
|---|---|---|
| Full name | Ligandrol (LGD-4033) | Myostatin Inhibitor Peptides (Anti-GDF-8) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Research compound |
| Mechanism | Selectively binds androgen receptors in muscle and bone, activating anabolic gene transcription while avoiding prostate activity. | Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth. |
| Molecular weight | 338.25 Da | 2,000-15,000 Da (varies) |
| Half-life | ~24-36 hours | 4-48 hours (design-dependent) |
| Bioavailability | ~90% oral | Variable (SubQ) |
| Typical dose | 5-10 mg | 50-500 mcg |
| Frequency | Once daily | 3-7x per week |
| Route | Oral | Subcutaneous |
LGD-4033 reported benefits
- Significant lean mass gains
- Bone density improvement
- Oral convenience
- Selective tissue activity
Myostatin Inhibitor reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
Related comparisons
Research and educational reference only. Not medical advice.